San Diego, CA -- (SBWIRE) -- 05/19/2016 -- An investigation was announced for investors of Echo Therapeutics Inc (NASDAQ:ECTE) shares over potential securities laws violations in connection certain financial statements.

Investors who purchased shares of Echo Therapeutics Inc (NASDAQ:ECTE), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements regarding Echo Therapeutics' business, its prospects and its operations were materially false and misleading at the time they were made.

Iselin, NJ based Echo Therapeutics, Inc. is engaged in developing a non-invasive, wireless continuous glucose monitoring system with use in the wearable-health consumer market and the diabetes outpatient market. Echo Therapeutics Inc reported that its annual Net Loss increased from $14.96 million in 2014 to $22.20 million in 2015.

Shares of Echo Therapeutics Inc (NASDAQ:ECTE) closed at May 18, 2016, at $1.61 per share.

Those who purchased shares of Echo Therapeutics Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com